Go back to trials list
Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia
Description
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.
Trial Eligibility
Inclusion Criteria: * Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification * Presence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood * Age ≥ 18 years and ≤ 60 years * Adequate hepatic function within 48 hours prior to induction chemotherapy * Adequate renal functions within 48 hours prior to induction chemotherapy * ECOG performance status within 48 hours prior to induction chemotherapy ≤ 3 * Eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified Exclusion Criteria: * Acute promyelocytic leukemia (APL) * Known clinically active central nervous system (CNS) leukemia * Severe liver disease * Active infections * Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) * Known infection with human immunodeficiency virus (HIV) * Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)
Study Info
Organization
Arog Pharmaceuticals, Inc.
Primary Outcome
Event-free survival (EFS)
Interventions
Locations Recruiting
City of Hope National Medical Center
United States, California, Duarte
Ronald Reagan UCLA Medical Center
United States, California, Los Angeles
US Davis Health
United States, California, Sacramento
Yale Cancer Center
United States, Connecticut, New Haven
Moffitt Cancer Center
United States, Florida, Tampa
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Acute Myeloid Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:
![Abbvie](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fabbvie%20bigger_c5e4f4af-fb3c-45ca-b9f0-831fb4c5f968.jpeg?alt=media)
![Astellas Pharma](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/university%2Fpublic%2Fshared%2Fastellas%20fo%20realz-100_8fd8c5cb-3421-4cfd-8aa6-07a70f67acf7.jpg?alt=media)
![Servier](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fservier_6f4f6f05-7255-45f8-8f3d-a07651617cbe.png?alt=media)